MedPath

Effect of Empagliflozin in diabetic nephropathy

Phase 3
Conditions
ephropathy and proteinuria in diabetic nephropathy patients taking empagliflozin.
Diabetes mellitus due to underlying condition with diabetic nephropathy
E08.21
Registration Number
IRCT20210906052395N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
96
Inclusion Criteria

Patient with type2 diabetes
over the age of 18 years
GFR<60 or albuminuria

Exclusion Criteria

Recent myocatdial infarction and PCI
Dialysis in the last ninety days
GFR<30
Renal failure for reasons other than diabetes
Recurrent urinary tract infections
History of amputation due to diabetes
Bladder cancer
Active diabetic foot ulcer
type 1 diabetes
Pregnancy and lactation
Major surgery performed in the last 28 days

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath